Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0024141 (
systemic lupus erythematosus
)
44,322
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We have identified the genes whose expressions are augmented in the blood cells of the patients with
systemic lupus erythematosus
(
SLE
) using the 'stepwise subtraction' technique along with microarray analysis. The expression levels of these genes were assessed by quantitative real-time reverse transcription polymerase chain reaction (RT-PCR) in 31
SLE
patients and 30 healthy controls. We found that the transcription levels of following eight genes were significantly increased in
SLE
patients; interferon (IFN)-alpha-inducible protein 27 (IFI27), IFN-alpha-inducible protein IFI-15K (G1P2), IFN stimulated gene 20 kDa (ISG20), epithelial stromal interaction 1 (EPSTI1), defensin-alpha (
DEFA3
), amphiregulin (AREG) and two genes of unknown function (BLAST accession nos AL050290 and AY358224 = SLED1). In comparison with idiopathic thrombocytopenic purpura (ITP), an organ-specific autoimmune disease, IFI27, G1P2 and SLED1 were preferentially upregulated in
SLE
. In contrast, AREG and AL050290 were more highly expressed in ITP than in
SLE
. We correlated changes in gene expression and clinical/laboratory features of
SLE
and found that expression of ISG20, EPSTI1 and SLED1 are significantly correlated with lymphocyte counts. Genes linked to IFN are well known to influence
SLE
, but several other novel genes unrelated to IFN signaling we report here would be useful to understand the pathophysiology of
SLE
.
...
PMID:Isolation and expression profiling of genes upregulated in the peripheral blood cells of systemic lupus erythematosus patients. 1676 99